Results 71 to 80 of about 60,298 (290)

Development of consensus recommendations on the management of vitiligo and the role of decapeptide in vitiligo by the delphi method

open access: yesIndian Journal of Dermatology, 2023
Background: Treatment of vitiligo is still a challenge in dermatology. Literature is sparse on the definitive clinical role of basic fibroblast growth factor (bFGF) in vitiligo patients.
Davinder Parsad   +20 more
doaj   +1 more source

The Coexistence of Coeliac Disease, Psoriasis and Vitiligo [PDF]

open access: yes, 2010
It has been defined that coeliac disease is associated with most of the autoimmune diseases including psoriasis and vitiligo. Here, a 26-year-old woman who was diagnosed palmoplantar pustular psoriasis and already had coeliac disease and vitiligo is ...
Ali Tahsin Güneş   +5 more
core   +2 more sources

Consensus on the Clinical Approach to Moderate-to-Severe Atopic Dermatitis in Spain: A Delphi Survey [PDF]

open access: yes, 2020
Background. The purpose of this study was to gather information on the current assessment and management of patients with moderate-to-severe AD in routine daily practice. Methods.
Armario Hita, José Carlos   +9 more
core   +3 more sources

Vitiligo - Part 1 [PDF]

open access: yesAnais Brasileiros de Dermatologia, 2014
Vitiligo is a chronic stigmatizing disease, already known for millennia, which mainly affects melanocytes from epidermis basal layer, leading to the development of hypochromic and achromic patches. Its estimated prevalence is 0.5% worldwide. The involvement of genetic factors controlling susceptibility to vitiligo has been studied over the last decades,
Tarlé, Roberto Gomes   +3 more
openaire   +5 more sources

BIOME cohort: Multi‐system microbiome dynamics and clinical outcomes in massive burn injury patients

open access: yesiMeta, EarlyView.
Massive burn injuries (MBIs) are associated with high mortality and disability rates, primarily due to microbial‐driven sepsis from extensive skin barrier loss and subsequent scar formation. This makes MBI a compelling model for studying multi‐system microbial dysbiosis following skin barrier destruction.
Runzhi Huang   +72 more
wiley   +1 more source

Identifying acne treatment uncertainties via a James Lind Alliance Priority Setting Partnership [PDF]

open access: yes, 2015
Objectives: The Acne Priority Setting Partnership (PSP) was set up to identify and rank treatment uncertainties by bringing together people with acne, and professionals providing care within and beyond the National Health Service (NHS). Setting: The
Andrews, Stephen   +11 more
core   +2 more sources

Autoantibody signatures in children with celiac disease, juvenile idiopathic arthritis, and polyautoimmunity

open access: yesJPGN Reports, EarlyView.
Abstract Objective To determine if multiplex autoantibody arrays can identify novel biomarker signatures in children with one or multiple autoimmune diseases (polyautoimmunity). Methods Plasma collected from children (18 years or younger) in the Boston Children's Hospital Precision Link Biobank for Health Discovery between January 2007 and June 2021 ...
Nan Du   +7 more
wiley   +1 more source

Public knowledge and attitude toward vitiligo in Saudi Arabia: A cross-sectional study

open access: yesJournal of Dermatology and Dermatologic Surgery, 2021
Background: Knowledge and positive attitude toward vitiligo would foster support for affected individuals, improving their sense of well-being and possibly treatment outcome.
Malak A M Algarni   +5 more
doaj   +1 more source

Vogt-Koyanagi-Harada Syndrome in a 10 Years Old Child [PDF]

open access: yes, 2011
The Vogt-Koyanagi-Harada (VKH) syndrome is a rare systemic disorder of uveitis, dysacousia, vitiligo, premature graying of the hair, eyebrows and eyelashes, and meningoencephalitis. Although frequently unrecognised,VKH may affect children.
Singh, T, Sufi, AR, Zargar, S
core   +1 more source

Characteristics of Adult Patients With Atopic Dermatitis Initiating Biologics and Janus Kinase Inhibitors in the CorEvitas Atopic Dermatitis Registry

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Biologics and Janus kinase inhibitors (JAKi) are two advanced systemic treatment options for patients with atopic dermatitis (AD). The decision to initiate one of these therapies is complex and may be driven by many factors.
Eric L. Simpson   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy